Key to radiation therapy is to apply a high tumor-destroying dose while protecting healthy tissue, especially near organs at risk. To optimize treatment for ion therapy not the dose but the dose multiplied by the relative biological effectiveness (RBE) is decisive. Proton therapy has been based on the use of a generic RBE, which is applied to all treatments independent of dose/fraction, position in the spread-out Bragg peak (SOBP), initial beam energy or the particular tissue. Dependencies of the RBE on various physical and biological properties are disregarded. The variability of RBE in clinical situations is believed to be within 10-20%. This is in the same range of effects that receive high attention these days, i.e., patient set-up uncertainties, organ motion effects, and dose calculation accuracy all of proton radiation effects. We conclude that, at present, RBE modeling in treatment planning involves significant uncertainties. To incorporate RBE variations in treatment planning there has to be a reliable biological model to calculate RBE values based on the physical characteristics of the radiation field and based on well-known biological input parameters. In order to do detailed model calculations more experimental data, in particular for in vivo endpoints, are needed.
affecting proton as well as conventional radiation therapy. Elevated RBE values can be expected near the edges of the target, thus probably near critical structures. This is because the edges show lower doses and, depending on the treatment plan, may be identical with the beam's distal edge, where dose is deposited in part by high-LET protons. We assess the rationale for the continued use of a generic RBE and whether the magnitude of RBE variation with treatment parameters is small relative to our abilities to determine RBE's.
Two aspects have to be considered. Firstly, the available information from experimental studies and secondly, our ability to calculate RBE values for a given treatment plan based on parameters extracted from such experiments.
We analyzed published RBE values for in vitro and in vivo endpoints. The values for cell survival in vitro indicate a substantial spread between the diverse cell lines. The average value at mid SOBP over all dose levels is ≈1.2 in vitro and ≈1.1 in vivo. Both in vitro and in vivo data indicate a statistically significant increase in RBE for lower doses per fraction, which is much smaller for in vivo systems. The experimental in vivo data indicate that continued employment of a generic RBE value of 1.1 is reasonable. At present, there seems to be too much uncertainty in the RBE value for any human tissue to propose RBE values specific for tissue, dose/fraction, etc. There is a clear need for prospective assessments of normal tissue reactions in proton irradiated patients and determinations of RBE values for several late responding tissues in animal systems, especially as a function of dose in the range of 1-4 Gy. However, there is a measurable increase in RBE over the terminal few mm of the SOBP, which results in an extension of the bio-effective range of the beam of a few mm. This needs to be considered in treatment planning, particularly for single field plans or for an end of range in or close to a critical structure.
To assess our ability to calculate RBE values we studied two approaches, which are both based on the track structure theory of radiation action. RBE calculations are difficult since both the physical input parameters, i.e., LET distributions, and, even more so, the biological input parameters, i.e., local cellular response, have to be known with high accuracy. Track structure theory provides a basis for predicting dose-response curves for particle irradiation.
However, designed for heavy ion applications the models show weaknesses in the prediction
Introduction
Proton radiation therapy has found increased worldwide application in recent years. Based upon the physical characteristics protons offer the advantage of a highly conformal high dose region, e.g., created by a SOBP, with the possibility of covering the tumor volume with high accuracy. At the same time this technique delivers lower doses to healthy tissue than conventional photon or electron techniques. Thus, the rationale for the clinical use of proton beams is the feasibility of delivering higher doses to the tumor, leading to an increased tumor control probability (TCP), due to the irradiation of a smaller volume of normal tissues than is feasible with other modalities. Due to the reduced treatment volume and a lower integral dose, patient tolerance is increased. Of particular interest for protons are those tumors located close to serially organized tissues where a small local overdose can cause fatal complication such as most tumors close to the spinal cord.
Clinical gains with protons have long been realized in the treatment of uveal melanomas, sarcomas of the base of skull, and sarcomas of the paravertebral region. Treatment plan comparisons show that protons offer potential gains for many other sites. Comparisons of treatment modalities (protons vs. photons) have been made on the basis of TCP and NCTP (Normal Tissue Complication Probability) calculations for cranial irradiation of childhood optic nerve gliomas by Fuss et al. (1) . Also, advantages of proton plans compared to photon plans have been shown for pediatric optic pathway gliomas (2) and for pediatric medulloblastoma/ primitive neuro-ectodermal tumors (3). Here, proton therapy offered a high degree of conformity to the target volumes and steep dose gradients, thus leading to substantial normal tissue sparing in high-and low-dose areas. Studies on various CNS tumors and pediatric patients with low-grade astrocytoma revealed that acute or early late side effects were low (4, 5). Another target used for comparative treatment planning is glioblastoma multiforme (6) where, due to a highly radioresistant tumor mass and due to extensive microscopic invasion, high doses to critical structures are difficult to avoid. A comparison of proton and X-ray treatment planning for prostate cancer has been published by Lee et al. (7) . Isacsson et al. studied X-ray and proton irradiation of esophageal cancer (8), locally advanced rectal cancer (9), and paraspinal tumors (10) showing that protons have therapeutic advantages over conventional therapy based on TCP and NTCP calculations. Osteo-and chondrogenic tumors of the axial skeleton, rare tumors at high risk for local failure, were studied for combined proton and photon radiation therapy (11). The potential advantages of protons over conventional photon therapy have also been demonstrated in various other types of tumors (6, 7, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . For advanced head and neck tumors a treatment plan comparison was done by Cozzi et al. (22) for five patients using 3D conformal and intensity modulated photon therapy and proton therapy. They distinguished between passive (23, 24) and active (25, 26) modulated proton beams. They concluded that looking at target coverage and tumor control probability there are only small differences between highly sophisticated techniques like protons or intensity modulated photons if the comparison is made against good conformal treatment modalities with conventional photon beams. The situation was judged to be quite different if organs at risk are considered. A treatment plan comparison for conventional proton, scanned proton, and intensity modulated photon radiotherapy, was performed by Lomax et al. (27) . Plans for each modality were performed using CT scans and planning information for nine patients with varying indications and lesion sites. The results were analyzed using a variety of dose and volume based parameters. They found that the use of protons could lead to a reduction of the integral dose by a factor of three compared to standard photon techniques and a factor of two compared to intensity modulated photon plans. Further, Yeboah and Sandison (28) compared optimized treatment plans for intensity modulated X-ray therapy (IMXT), VEEHT (very high energy electron therapy), and intensity modulated proton therapy (IMPT, (29)) for prostate cancer. They concluded that IMPT delivered a mean rectal dose and a bladder dose that was much lower than achievable with the other two modalities. IMPT was also superior in target coverage.
It is evident from these photon/proton comparisons that even with the rapid development of intensity-modulated dose delivery with electrons and photons, protons are capable of much higher dose conformity, in particular for intensity modulated proton techniques (27, (30) (31) (32) . The reduction of integral dose with protons is also significant. Although it is true that the clinical relevance of low doses to large volumes is not well known (except perhaps in organs with a parallel or near parallel architecture), there are cases where a reduction in overall normal tissue dose is relevant, e.g., for pediatric patients.
Due to the increasing number of patients treated with protons more and more patients will be considered as potential proton therapy candidate. In order to quantify accurately the relative merits of treatment modalities and treatment techniques, it is important to adopt biologically sound cellular dose-response models for tumors and normal tissues and implement them into treatment planning. In proton therapy treatment planning, the proton dose has to be adjusted to Cobalt Gray Equivalent (CGE) using a RBE value. The only fundamental reason for applying a RBE value is to ensure that radiation oncologists can benefit from the large pool of clinical results obtained with photon beams. The RBE adjusted dose is defined as the product of the physical dose and the respective RBE describing the radiosensitivity of the tissue after ion irradiation compared to photon irradiation at a given level of effect. Proton therapy is based on the use of a single RBE value (equals 1.1 at almost all institutions), which is applied to all proton beam treatments independent of dose/fraction, position in the SOBP, initial beam energy or the particular tissue. A generic RBE is only a rough approximation considering experimentally determined RBE's for both in vitro and in vivo systems (33).
To benefit from newly developed imaging techniques, allowing better tumor localization or even image-guided therapy (34), and new treatment techniques (e.g., beam scanning (25) or intensity modulation (32) using small dose spots), precise treatment planning is necessary. Any RBE effect does not only change the dose at any specific point in the target but will have influence on the dose homogeneity. In general, the associated heterogeneity in the RBE adjusted dose always exceeds that in physical dose because the response of both normal and malignant tissues is a non-linear function of dose (35). RBE effects may influence judgment in dose escalation studies and fractionation schedules. It is believed that treatment regimes with multiple small fractions per day (hyperfractionation) can be less damaging to slowly proliferating tissues than higher single doses. In studying hyperfractionation effects one has to keep in mind that, for protons, in vitro radiobiological measurements show an increasing RBE with decreasing dose (33, 36) . The RBE of principal concern is that of the critical normal tissue/organ(s) immediately adjacent to or within the treatment volume, i.e., the determinant(s) of NTCP. Clinicians and treatment planners are often reluctant to having the SOBP abutting a critical structure thus not utilizing one advantage of protons, namely the sharp distal fall-off. As an example, the experience at MGH in the proton treatment of 348 patients with skull-base sarcomas has been assessed by Debus (37) for Grade III-V brain stem morbidity relative to the effective dose distribution in CGE. To allow for the modest increase in RBE over the final few mm of the SOBP, for those patients in which the end of range of the beam was within the brain stem, only a small fraction of the cross section of the brain stem was covered by such a field and the maximum dose/fraction from such a beam was 0.9 CGE, i.e., the total dose from that field was limited to <10 CGE. A better understanding of RBE uncertainties may allow treatments where the proton beam is directed towards a critical structure (although other treatment uncertainties will still require safety margins).
Experimentally Determined RBE Values

Literature Survey
The published results of experimental determinations of RBE for in vitro (cell survival only) and in vivo systems in a SOBP are presented in Figures 1-2 showing RBE's as a function of dose per fraction. All RBE's have been adjusted to be relative to 60 Co and specified in terms of the photon dose because the majority of original data is given relative to 60 Co (If not, as an approximation, a factor of 1.15 for 250kVp X-rays, 1.175 for 180 kVp X-rays, 1.2 for 120
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Technology kVp X-rays, and 1.0 for 137 Cs (38) for in vitro data and 1.0 as an average for X-rays in vivo (39, 40) was applied for all dose levels.). Proton beams are referred to in terms of the maximum proton energy. Clinical beams typically fall into two energy ranges: 65-100 MeV, used almost entirely for ocular tumors with doses/fraction of [6] [7] [8] [9] [10] [11] [12] [13] [14] MeV beams employed against more deeply sited lesions at 1.8-4 CGE/fraction. In addition, proton beam radiosurgery is performed using higher doses, e.g., about 15 CGE. For the in vitro data from clinical beams, the range of estimated RBE's in the center of the SOBP is from 0.86 to 2.1 with a mean of 1.22 and a standard error of 0.02. The in vivo RBE's (mid-SOBP) range from 0.73 to 1.55 with a mean of 1.10 and a lower standard error of 0.01.
Thus, there appears to be a lower RBE with a lesser spread in vivo than obtained from in vitro systems.
In addition to the SOBP data, RBE's for cell survival for near-monoenergetic proton beams of <8.7 MeV are presented in Figure 3 (as a function of energy and dose per fraction). These are research beams with only indirect relevance to the clinical situation since these protons contribute typically less than a few percent to the total dose at the center of a SOBP (41). However, data from those studies are valuable in developing cellular response models since they provide a well-defined LET. Because they have a significantly higher LET than clinical proton beams, the dependencies of their RBE's on factors such as dose level represent an upper limit to that feasible for clinical proton beams. The low energy proton data show, not surprisingly, a higher average RBE (mean RBE is 1.71 ± 0.69 at doses >1 Gy).
RBE as a Function of Tissue or Endpoint and Dose or Dose/Fraction
Most of the in vitro studies are based on the survival of V79 cells (6, (13) (14) (15) (18) (19) (20) . These data show on average a significantly higher RBE than the ones from other cell systems, e.g., human tumor cells. RBE's greater than 1.3 were observed in 3 reports on V79 cells, viz. 2.1, 1.6, 1.5 and 1.45 (42-44). RBE values for 3 cell lines studied in vitro in clinical beams increased as dose was decreased over the range of 4 to 1 Gy (42) (43) (44) (45) (46) . In contrast, measurements in some laboratories (42, 46, 47) did not indicate a change in RBE as dose decreased.
In some publications not only the RBE values at specific doses are given but the α and β parameters for the response curves of proton and reference radiation (42, 44, 45, (48) (49) (50) (51) .
Based on the analysis of the reconstructed cell survival curve all but two experiments in vitro (on human colon carcinoma (42) and on V79 cells (52), reaching eventually RBE values below 1.0) show an increasing RBE with decreasing dose. In summary, the majority of RBE determinations in vitro show the RBE for cell survival increase as dose decreases (However, for the data fitted with the linear-quadratic model that may be the result of the underlying theory).
End-points for non-lethal injury, e.g., gene mutation, chromosomal abnormalities and carcinogenesis, are also of clear clinical relevance. RBE values for the induction of dicentrics and rings in peripheral lymphocytes at doses of 0.1-8 Gy were determined in the SOBP of a 70 MeV proton beam (53) . RBE values increased with increasing depth in the distal half of the SOBP, and increased with decreasing dose in the SOBP. A study on mutation induction at the HPRT locus in V79 cells with low energy proton beams showed RBE values to be higher for mutation compared to cell survival by up to 17% (54) . However, comparison with cell survival RBE values showed no significant difference for radiation induced DNA damage of thyroid follicular cells (55) and for micronucleus formation and cell survival for Chinese hamster cells C1-1 (56 (55) 
Single Dose RBE Values for Other Tissue Systems:
The RBE for acute effects of proton whole-body irradiation on the distribution and function of leukocyte populations in the spleen and blood was found to be ≈1.0 by Kajioka et al. (75) for 3 Gy at 0.4 Gy/min. Single dose RBE's were determined by Urano et al. (73) , for growth suppression of tail vertebrae, lens opacification and gain in testis weight of the C3H mouse. The resultant RBE's were 1.02 -1.23.
The dependency on dose, i.e., increasing RBE with decreasing dose, appears to be far less in vivo compared to the in vitro data. However, RBE values from in vivo systems at doses of <4Gy/fraction are quite limited. The concern that RBE may be underestimated at clinical dose levels (5) is not confirmed by the in vivo studies. Evaluation of the statistically significant difference in RBE between in vitro and in vivo systems should deal explicitly with the fact that the former uses as the end-point the killing of single cells of one cell population (colony formation). The in vivo response reflects the more complex expression of the integrated radiation damage to several tissue systems (cell populations).
In addition, the in vivo data refer to various different biological processes. Accordingly, some level of non-concordance between RBE values determined by the two different systems is not unreasonable.
It was suggested that there may be systematic and inverse variation in RBE with the cell or tissue α/β-ratio (α and β being the parameters of the linear-quadratic equation) at low dose per fraction (76). The implication is that RBE's at low dose/fraction may be higher for late than early responding tissue and that cells exhibiting a high α/β-ratio will not exhibit dose dependent RBE variations. These findings are interesting, e.g., with respect to treating prostate patients with protons since it has been found that the α/β-ratio for prostate might be rather low. The two in vitro studies that show a decreasing RBE with decreasing dose are the one on human colon carcinoma (42) and one on V79 cells (52), both reported having a high α/β-ratio. In this connection it is important to note that the two late response tissues investigated in vivo (endpoints around 250 days post irradiation), i.e., lung lethality (71) and skin contraction (70) did not show the expected increase in RBE at low doses.
In summary, the need is clear for substantial additional RBE values on in vivo systems, particularly late responding tissues at 1 -3 Gy per fraction, to provide clinicians with better guidelines for planning patient treatment.
RBE vs. Position in the SOBP (LET)
The effect of radiation on cells and tissues is a complex and not entirely understood function of the properties of the cell or tissue and the microdosimetric properties of the radiation field. The LET is only one parameter to characterizes the microdosimetric structure and is only one of several determinants of radiation response. Nevertheless, a change in response of a cell population to a defined physical dose by different radiation beams is generally accepted as due to differences in LET. This is based on the concept that ionization density within the sensitive cellular structure (e.g., DNA) increases with LET and that production of non-reparable lesions increases with ionization density. The impact is a reduction of the width of the shoulder of the cell survival curve with progressively higher RBE's as doses are lowered. In general as LET increases, the RBE increases, eventually reaching a maximum and then decreasing (77). A small increase in the proton RBE across the SOBP and the extension of the penetration of the beam by a few mm is expected because of an increasing LET (41, 78-80).
The RBE in the plateau region and the SOBP has been determined by several investigators. The ratio of RBE's of mid-SOBP/plateau for 2 Gy is 1.03, with a standard deviation of 0.02, based on all reported RBE's and on calculated RBE's using the reported α and β values for individual experiments.
The published RBE's do suggest a modest increase with depth in the SOBP. Further, there is a relatively clear rise in effective dose in the region close to the distal end of the SOBP, and a modest few mm extension in depth of the effective dose distribution. Reported RBE values for the 65 -100 MeV protons tend to increase gradually throughout the SOBP (42-47, 81). This trend was less pronounced for high energy beams having wider SOBP's (49, 50, 82) . A fit of all available RBE values determined over the SOBP showed an increase in RBE of about 5% at 4 mm and about 10% at 2 mm from the distal edge, relative to the mid-SOBP RBE. The rise in LET and RBE at the trailing edge of the distal most Bragg peak of the SOBP results in an extension of the biologically effective range by a few mm (44, 46, 82) . The effects of an increasing RBE with depth could be compensated for in the physical dose distribution since for some endpoints at least relative RBE values are known well enough.
Theoretically Determined RBE Values
Simulation of Proton Therapy Biology
A determination of RBE on a three-dimensional grid for a given treatment plan cannot be achieved with measurements but with model calculations (for proton studies see (41, 78, 79, 83, 86, 87) ).
Frequently applied phenomenological models in radiation therapy are "track structure models" based on the theory by Butts and Katz (88) . This term, which originated in the late sixties, is misleading since, in fact, the track structure is neglected using amorphous tracks with a δ-ray halo around the track. Track structure theory in the form of two different models, originally designed to describe radiation effects of heavy ions and neutrons, is applied in radiation biology and radiation therapy. These are the so-called ATP (Amorphous Track Partition) (88-91) and ATL (Amorphous Track Local effect) (92-95) models. Detailed comparisons can be found elsewhere (80, 96, 97) . The influence of the input parameters on the outcome of the models and the predictions of the two models with respect to cell survival of V79 cells for protons has been investigated for typical proton energies and doses in proton radiation therapy (80). Figure 4 shows calculated versus experimental RBE values (for protons and αparticles) for inactivation of V79 cells as well as calculated values (using the ATP model) for inactivation of mouse lymphoma cells and human skin fibroblasts (84).
Track structure theory assumes a simplified biological target and a simplified amorphous particle track. The track is described by its radial dose distribution due to δ-electrons originating from ionization events. The target is assumed to be an infinitely thin disc, its size or cross section being endpoint dependent. This assumption ensures that there is no LET variation from particles, or even stopping particles, within the target (track segment condition). For protons, this becomes questionable for energies below approximately 1 MeV, depending on the thickness of the cell (98). One also has to keep in mind that radiosensitivity might depend on the shape of the cell nucleus (99-101).
The biological effect is calculated from the overlap of the track with the target. For equal absorbed dose, the microscopic response due to δ-rays is assumed to be identical to that due to secondary electrons from γ-rays. Thus, knowledge of the response of the medium to γ-rays, coupled to knowledge of the spatial distribution of δ-ray dose, yields the spatial distribution of response about the path of a single charged particle (88). Due to the use of the γ-ray doseresponse curve as reference, the mechanistic details of radiation action are masked. The different efficiencies of different types of radiation result solely from different dose deposition patterns within the target and are not based on LET alone. As input, the radiation field has to be known in the form of particle type and energy distributions obtained, for example, from Monte Carlo simulations (41, 83, 102) . From this, the radial distribution of dose around the particle track originating from ejected secondary electrons is calculated. Various models exist to calculate this radial deposited energy (see e.g., (103, 104) and references therein). The dose deposited as a function of the distance, r, to the ion path can be written as a function of 1/r 2 up to a limit determined by the maximal radial penetration of δ-rays. The radial dose profile is related to the LET via radial integration of the contributions from dose deposited via δ-rays, dose due to excitations, and energy deposition due to nuclear stopping.
Track structure theory involves some simplifications. In reality, the track volume for particles is mostly empty, especially for protons, with only a few δ-ray events on the scale of the cell nucleus size. The stochastic nature of particleinduced events is not taken into account applying a continuous radial dose distribution defining the track shape. The higher the mean free path of the ion, the more important statistical fluctuations, i.e., the stochastic δ-ray emission, will be (105-107). The use of a non-stochastic radial dose distribution to determine biological effect also neglects the observed increased biological effectiveness observed with low-energy electrons (108, 109). Track structure theory ignores details of the actual mechanisms of energy loss and evades any need for explicit knowledge of the fluctuation in energy deposition. One can argue that the response to γ-rays incorporates both fluctuations and the properties of the target so that there is no need to implement fluctuations of the radial dose around the ion's path; the effects produced by a local dose of δ-rays is compared in the theory with those produced by an equal dose of γ-rays. This is true even where the δrays are sparse, at large distances from the ion's path, because, at low doses of γ-rays, secondary electrons are also sparse. Further, the models assume a uniformly distributed radiosensitivity throughout the cell nucleus, and the same radiosensitivity is attributed to all cells of a population. Radiosensitivity depends also on the cell cycle stage (110). Repair is not included other than by a fit of the shoulder of the γ-ray response curve. Track structure theory again addresses these issues through the equivalence of δ-ray action by different ionizing radiations.
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The ATP and ATL models are based on different calculation schemes and different sets of initial parameters. The ATP model provides a set of equations to predict inter-track and intra-track radiation response whereas the ATL model is based on Monte Carlo simulations. One significant difference between the two models is the treatment of local doses. In the ATP model, the local dose is averaged over sub-targets and the effect is calculated and integrated over all possible impact parameters. The ATL model considers the entire nucleus as target using the local effects originating from local dose depositions inside infinitesimal compartments. The radiation response is averaged over the nucleus. In fact, the point-target approach (ATL model) is as well an approximation as the extended sub-target approach (ATP model). Due to the averaging of doses over extended sub-targets in the ATP model, it is likely that the ATP model is more robust with respect to radial dose fluctuations. Both models have to handle the singularity at low doses, either by a dose cut-off at small radii (ATL) or by dose averaging over sub-target areas (ATP). The ATP model predicts unrealistic target sizes if interpreted in a mechanistic way and introduces an empirical scaling of the cross-section from sub-cellular to cellular response. However, the model is based on a set of input parameters fitted on experimental data for a phenomenological characterization of a specific endpoint. On the other hand, the ATL model requires an adjustment of certain parameters, which are not necessarily well known, and that have a significant influence on the simulation outcome. Both models have been shown to be in good agreement with experimental data for heavy ions (93, 111, 112) . Figure 5 compares the predictions of the ATP and the ATL model for protons regarding the inactivation of V79 cells in vitro. Both models predict proton survival curves reasonably well but neither shows good agreement with experimental data over the entire range of proton energy and absorbed dose considered. The ATL model seems to overestimate the cellular response for very low-LET protons, which could be related to the radial dose parameterization but is presumably mainly due to the point-target concept. The ATP model shows an underestimation of cellular response. A modification of the scaling factor relating subtarget size and cell nucleus size was therefore suggested (80 
Assessment of Theoretical Proton RBE Values
The studies regarding RBE values in proton beam therapy using various biophysical cell-effect models clearly show an increasing RBE with increasing proton LET. The consequence is an increasing RBE with increasing depth in a treatment field. There is a greater effect for lower energy beams (113) . An extensive study on the RBE as a function of depth for different beam energies and target sizes used the endpoint of intestinal crypt regeneration in mice (79) . For this purpose, the microdosimetric response function model was used, which, because it is based on the initial slope of cell response curves, can only predict RBE values for a low dose interpolation. Using the ATP model, a study regarding the spatial variation of proton RBE values for beam conditions suited for the treatment of ocular melanoma showed an RBE increasing with depth and decreasing absorbed dose for the endpoints inactivation of V79 and CH2B2 hamster cells (78) (see Figure 6 ). RBE values at the distal end of the considered SOBP up to 1.3 and 1.5 were found at a dose of 14 Gy and 2 Gy, respectively. At the distal edge of the SOBP the RBE rises sharply. Assuming energies around 65 MeV, as is common for treatment of ocular melanoma, this can lead to a shift up to 1 mm. Besides the shift of dose, the biologically equivalent dose in the treatment volume will be non-uniform due to the variable RBE.
In separate studies, the influence of the beam modulation technique on dose and RBE was studied (41, 83). As dose can be described as the integral over fluence times LET, it is evident that in a mixed radiation field similar doses can be achieved with different particle energy distributions. Isodose contours are isoeffect contours only if the energy spectra of the accompanying particles remain constant. On this condition, the beam delivery technique used to build a SOBP can influence the RBE. An increasing RBE with depth within the SOBP was found and it was shown that the beam modulation technique influences the proton energy spectra, the fluence, the LET, and the RBE within a SOBP although the dose remains constant. The higher the energy used for modulation the lower are the average LET and the RBE and the higher is the proton fluence. Within a SOBP (6 -13 cm; RBE for aerobic survival of Chinese hamster cells, CH2B2; 2 Gy biological dose) the RBE calculated with the ATP model increased from ≈1 to ≈1.18 and to ≈1.16, for modulation with a 137 MeV and a 250 MeV beam respectively. Distal to the SOBP the modulation dependence was much higher. For a SOBP between 1.5 and 3.2 cm the RBE increased up to 1.5 and to 1.2, for a modulation with a 61 MeV and a 155 MeV beam respectively.
LET distributions in the SOBP depend on the beam delivery technique with implications for beam scanning (e.g., distal edge tracking techniques) (41, 83) . The role of nuclear interactions is also very important as they cause high LET parti-cles throughout the treated volume mainly affecting the area proximal to the SOBP (84, 85). Based on simulated threedimensional dose distributions from primary and secondary particles it was found that the effectiveness of proton beams compared to X-rays is determined by secondary particles (mainly protons, neutrons and α-particles) upstream the Bragg peak. In the Bragg peak region, the RBE is almost entirely determined by primary protons since the fluence of secondaries is decreasing with increasing depth (84).
Experimental data suggest that the RBE of protons compared to X-rays may be determined by the α/β-ratio of the X-ray survival curve (76). This observation was explored theoretically with the result that the RBE can not be predicted by the α/β-ratio alone (86). However, although there is no direct correlation between the proton RBE and the parameters describing the X-ray survival curve, model calculations predicted a tendency for late-responding tissues (low α/β) to have higher RBE values than early-responding tissues (high α/β). These calculations reinforced the experimental findings, but also strongly suggest that there are circumstances in which there is no tendency for RBE to increase with increasing α/β or, even, could be reversed.
Despite these studies, one should be cautious by interpreting theoretical RBE values. Dependencies of RBE values on specific physical or biological parameters may not be true model predictions but may be a result of the underlying theory on which the phenomenological model is based. For example, a model, which is based on the characterization of the X-ray survival curve by the pure linear-quadratic equation, may not be able to explain the effect of low-dose hypersensitivity. By design, models based on the track structure theory exclude proton RBE values lower than 1.0 and also demand an increasing RBE with decreasing dose. This is due to the concept of relating the biological effect to the cellular dose deposition pattern.
A potential problem of implementing model calculations into routine treatment planning is the fact that it is very difficult, if not impossible, to transfer radiosensitivity data from in vitro measurements to in vivo situations. The presence of hypoxic cells and repopulation would both decrease the total cell kill during fractionated radiation treatment as compared to predictions based on in vitro results. Lack of full repair would make the survival values measured in vitro lower rather than higher. Intracellular contact might also influence the relationship between in vivo and in vitro results. Cell irradiated in spheroids or solid tumors can show higher survival than when irradiated as a suspension or mono-layer culture. This effect is apparently due to increased repair capacity for cells in contact.
The interpretation of theoretical RBE values and their clinical significance is often based on the simulation of the cell survival of V79 cells, since numerous sets of input parameters are available for this endpoint. Although this is certainly appropriate to assess relative RBE values, it has to be considered that cell survival experiments with V79 cells in vitro show, on average, higher RBE values than experiments on human tumor cells. More measurements regarding endpoints in vivo are necessary to extend the number of available parameter sets for model calculations.
Conclusion
At present, the continued use of a generic RBE of 1.1 in proton beam radiation therapy is appropriate. This does not mean that there are no tissues, whose RBE differs to a clinically important extent from the value of 1.1. Rather, in vivo laboratory evidence does not warrant a change in current practice. The current uncertainties in experimental RBE values are higher than the expected RBE variation in a treatment field. There are multiple treatment parameters affecting the RBE, i.e., tissue, endpoint, dose level, maximum beam energy, width of SOBP, position within the SOBP etc. A compelling argument for keeping the currently applied clinical practice of using a generic RBE is the fact that there is no published report to indicate that the RBE of 1.1 in the center of a SOBP is low. Presumably, would the RBE be erroneously underestimated by 10%, the increase in compli-cation frequency would have been noticed. On the other hand, one has to keep in mind the limited number of patients for some tumor sites and the difference in dose distribution between photon and protons. In addition, a substantial proportion of patients with long follow up were treated by a combination of both proton and photon beams while new clinical trials are mostly designed for proton therapy only. However, elevated RBE values and a clinical impact could be expected at the distal end of a treatment field. This is why in treatment planning one usually tries to avoid having the SOBP abutting a critical structure.
Nevertheless, to increase treatment accuracy the implementation of RBE variations in treatment planning is certainly desirable. But, model calculations can only be as accurate as the biological experiments from which the model parameters were extracted. There is a clear need for additional experimental studies on late responding tissues in laboratory animals systems to examine the dependency of RBE particularly on dose/fraction but also to explore the RBE for specific tissue types, e.g., CNS or kidney. 
